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Abstract
Background Biochemical bone turnover markers are useful tools to assess bone remodeling. C-terminal telopeptide of type 
I collagen (ß-CTX) has been recommended as a reference marker for bone resorption in research studies.
Methods We describe the results of a multicenter study for routine clinical laboratory assays for ß-CTX in serum and plasma. 
Four centers (Athens GR, Copenhagen DK, Liege BE and Sheffield UK) collected serum and plasma (EDTA) samples from 
796 patients presenting to osteoporosis clinics. Specimens were analyzed in duplicate with each of the available routine 
clinical laboratory methods according to the manufacturers’ instructions. Passing-Bablok regressions, Bland–Altman plots, 
V-shape evaluation method, and Concordance correlation coefficient for ß-CTX values between serum and plasma specimens 
and between methods were used to determine the agreement between results. A generalized linear model was employed to 
identify possible variables that affected the relationship between the methods. Two pools of serum were finally prepared and 
sent to the four centers to be measured in 5-plicates on 5 consecutive days with the different methods.
Results We identified significant variations between methods and between centers although comparison results were gener-
ally more consistent in plasma compared to serum. We developed univariate linear regression equations to predict Roche 
Elecsys®, IDS-iSYS, or IDS ELISA ß-CTX results from any other assay and a multivariable model including the site of 
analysis, the age, and weight of the patient. The coefficients of determination  (R2) increased from approximately 0.80 in 
the univariate model to approximately 0.90 in the multivariable one, with the site of analysis being the major contributing 
factor. Results observed on the pools also suggest that long-term storage could explain the difference observed with the 
different methods on serum.
Conclusion Our results show large within- and between-assay variation for ß-CTX measurement, particularly in serum. 
Stability of the analyte could be one of the explanations. More studies should be undertaken to overcome this problem. Until 
harmonization is achieved, we recommend measuring ß-CTX by the same assay on EDTA plasma, especially for research 
purposes in large pharmacological trials where samples can be stored for long periods before they are assayed.
Keywords C-terminal telopeptide of type I collagen · ß-crosslaps · ß-CTX · Bone turnover markers · Bone resorption · 
Harmonization
Introduction
Determination of C-terminal telopeptide (β-CTX) and N-ter-
minal propeptide (PINP) of type I procollagen as reference 
markers of bone resorption and formation, respectively, 
is recommended analytes since 2010 by the International 
Osteoporosis Foundation (IOF) and the International Federa-
tion of Clinical Chemistry and Laboratory Medicine (IFCC) 
Joint Working Group on Bone Marker Standards (WG-BMS) 
[1]. As a result, these markers are now recommended by 
IOF, the European Calcified Tissue Society (ECTS) and the 
Society for Clinical and Economic Aspects of Osteoporo-
sis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) 
as useful tools for monitoring adherence of patients with 
osteoporosis to therapy with oral bisphosphonates [2, 3]. 
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One of the major issues that impede the implementation of 
these bone turnover markers (BTMs) in clinical practice is 
the lack of standardization between the different methods 
available on the market. For PINP, we have recently shown 
that the two automated methods, IDS-iSYS (Boldon, UK), 
and Roche Elecsys® total P1NP assay run on cobas e fam-
ily instruments (Mannheim, Germany) provided results that 
could be used interchangeably, allowing the application of 
similar reference ranges whatever the method, which is an 
important finding for the routine use of biomarkers outside 
the United States [4, 5]. Indeed, in that country, the only 
approved method is the Orion UniQ manual radio-immuno-
assay (Espoo, Finland), which presents a significant propor-
tional bias compared to the two automated methods.
β-CTX can also be measured by two automated meth-
ods, IDS-iSYS and Roche Elecsys® β-CrossLaps assay run 
on cobas e family instruments, as well as with a manual 
ELISA also marketed by IDS. Previous studies have, how-
ever, shown that there was significant disagreement between 
the results generated from patient samples by these three 
β-CTX assays [6]. Hence, in order to establish the clinical 
value of β-CTX as a reference bone resorption biomarker, 
harmonization of the results from different assays for these 
biomarkers is necessary. The IFCC and IOF established 
a Joint Working Group for the Standardization of Bone 
Marker Assays (WG-BMA) in 2012, which became a Joint 
Committee in 2019 to, among other tasks, evaluate the har-
monization of β-CTX assays. In this study, we report the 
results of the comparison of β-CTX results generated by 
each of the available routine clinical assays on the samples 
of the patients enrolled in the multicenter study for which we 
have already reported the results for PINP [5].
Material and Methods
Patients and Samples
The characteristics and the protocol of this study have 
already been described elsewhere [5]. Briefly, four cent-
ers located in Athens (Greece, GR), Copenhagen (Den-
mark, DK), Liege (Belgium, BE), and Sheffield (United 
Kingdom, UK) took part in the study. According to the 
agreed protocol, each center recruited 200 patients attend-
ing a local osteoporosis clinic. Patient blood samples were 
collected in  K3-EDTA tubes for analyses on plasma and in 
tubes with gel for analyses on serum. Demographic data, 
including sex, age, fasting status, current medications, and 
bone mineral density (BMD), were also collected.
Simultaneously, each center was asked to run 2 serum 
pools in 5 replicates over 5 consecutive days, on each instru-
ment without recalibration according to CLSI EP15-A3 
[7]. This performance study was run in parallel with the 
measurements of the patients’ samples. The two serum pools 
were constituted in BE using remnant human samples that 
had been stored at − 80 °C for > 5 years. These samples were 
mixed together according to their original value to target a 
final β-CTX concentration of ≈300 and ≈1000 ng/L. After 
thorough homogenization for 1 h on a rotating plate, pools 
were centrifuged and aliquoted. The aliquots were stored 
at − 80 °C until shipment on dry ice to each participating 
center. Each center, thus, received 5 aliquots (1 for each day) 
for each instrument (Fig. 1).
Analytical Methods
The two in-vitro diagnostics (IVD) companies producing 
β-CTX assay kits (IDS and Roche) provided reagents and 
calibrators to the participating laboratories. All reagents 
were from the same lot, and a single calibration was used 
(except for the ELISA). IDS provided reagents for the iSYS 
analyzer and ELISA kits whereas Roche provided reagents 
for the cobas e 411 analyzer which was the instrument used 
in all centers. All the laboratories had previous experience 
in running these methods and all assays were run in all labo-
ratories, except IDS ELISA which was not run in the UK. 
Manufacturers claim that β-CTX can be measured either in 
serum or plasma. Hence, plasma and serum samples were 
run in duplicate according to the manufacturers’ instruc-
tions, and results were calculated if the standard curves and 
the manufacturers’ supplied internal quality control (QC) 
specimens were within the specifications.
Statistical Methods
MedCalc (Mariakerke, BE) was used to calculate the Pass-
ing-Bablok regressions between serum and plasma and 
between methods as well as Bland–Altman plots. The coef-
ficients of variations were calculated on duplicates to deter-
mine the repeatability of each assay. The mean of the dupli-
cates was used to compare the results. The Mann–Whitney 
test was used to compare the medians.
The familiarization panel was analyzed per level using an 
ANOVA model accounting for the effects of center, day, and 
the interaction between day and center, and the QC results 
between centers were compared with ANOVA, followed by 
Tukey’s multiple comparison test with the 95% confidence 
intervals method (Graphpad Prism 6).
Because the agreement between results indicated consid-
erable deviation from the ideal situation (slope ≠ ‘1’, inter-
cept ≠ ‘0’,  R2 ≠ 1), the GLMSELECT procedure, using the 
backward selection option in SAS 9.4 (SAS Institute Inc., 
Cary, NC, USA), was applied to establish a generalized 
linear model (GLM) for each comparison with the aim of 
identifying variables which affected the differences between 
methods and, ultimately, to obtain a more acceptable 
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prediction model. GLMSELECT provides t values for the 
coefficients (instead of p values). An absolute t value > 1.96 
corresponds with a p value < 0.05. The larger the absolute t 
value, the more important the coefficient in the GLM.
Since small deviations from the ideal situation will be sta-
tistically significant because of the (very) large sample size 
of this study, we defined specifications corresponding to the 
desirable bias of 12.6% based on β-CTX biological variation 
according to Cavalier et al. [8] for the slope and ± 50 ng/L 
for the intercept corresponding to the limit of quantification 
of the assays to build V-shape limits (defined as y = − 0.126 
x − 50 and y = 0.126 x + 50) for the regression of differ-
ences on averages. We calculated the percentages of samples 
comprised between the V-shape limits and considered that 
methods were equivalent if 90% of the samples were com-
prised within the limits.
Finally, we also used Mecalc to calculate the concordance 
correlation coefficient (CCC), which evaluates the degree 
to which pairs of observations fall on the 45° line through 
the origin according to Lin et al. [9] and the strength of 
agreement according to Mc Bride et al. [10] as well as the 
Pearson correlation coefficient (ρ), which measures how far 
each observation deviates from the best-fit line and is, thus, 
a measure of precision, and a bias correction factor (Cb) that 
measures how far the best-fit line deviates from the 45° line 
through the origin and is, thus, a measure of accuracy. The 
strength of agreement is considered as “poor” when the CCC 
is < 0.90, “moderate” when CCC is comprised between 0.90 
and 0.95, “substantial” between 0.95 and 0.99 and “almost 
perfect” when CCC is > 0.99.
Results
All the calibration curves were accepted by the instruments, 
and all the QCs were within the specifications provided by 
the manufacturers in all participating centers.
Patients
796 patients (692 women, 104 men) were included in the 
study. Mean age (± SD) was 66.1 (± 11.7) years and mean 
BMI was 25.9 (± 4.8) kg/m2. There were mean age differ-
ences between patients recruited at the various centers: GR 
had the youngest patient group (mean age = 61.6 ± 8.8) and 
DK had the oldest patient group (mean age = 70.1 ± 11.3). 
All patients were in the fasting state in BE and GR whereas 
this was not necessarily the case in DK and UK. Samples 
Remnant sera





1 aliquote per /day
Pool 2
β-CTX≈1000 ng/L
Fig. 1  Preparation of the pools for the performance study evaluation
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were collected between April 2014 and April 2016 in BE, 
between April 2016 and November 2016 in UK, April 2015 
and March 2016 in DK and between October and Decem-
ber 2016 in GR. All samples were stored at − 80 °C until 
determination, which occurred between December 2016 and 
January 2017 in all four centers.
Regarding treatment, 65.8% of patients were taking cal-
cium, 60.8% vitamin D, 11.1% vitamin D analogs, 25.9% 
bisphosphonates, 0.3% strontium ranelate, 9.0% denosumab, 
2.0% teriparatide, and 1.1% were treated by selective estro-
gen receptors modulators.
Results of the Performance Evaluation Study
Analysis of the Results
Mean of pools were quite different according to the meth-
ods: 173.9 ± 19.7 ng/L and 763 ± 102 ng/L for the Elecsys 
assay on levels 1 and 2, respectively, vs. 81.6 ± 12.7 ng/L 
and 650 ± 59 ng/L for iSYS and 168 ± 32 and 737 ± 162 ng/L 
for ELISA.
For Roche, mean values were similar for BE, DK, and 
UK but consistently lower for GR, and the standard devia-
tions in GR were consistently greater each day. On day 5, the 
mean in UK was significantly lower than on all other days 
in BE and DK. The ANOVA model explained 92.6% of the 
variation in the results with center, day, and the interaction 
between center and day accounting for 78.2%, 3.4%, and 
10.9% of that variation, respectively. Similar findings were 
obtained for pool 2, but in this case, on day 4, DK showed a 
very large difference between the individual results.
For iSYS, distribution of the values was normal, but mean 
values per center were also quite different, ranging from 68.1 
to 96.9 ng/L, indicating also a possible center effect. 80.4% 
of the variation in the data was explained by the ANOVA 
model and the variable center, day, and interaction term 
accounted for 74.7%, 1.5% (non-significant [NS]), and 4.2% 
(NS), respectively. The same conclusions could be drawn 
from the observation of the results of pool 2.
For ELISA, even though there was a clear center effect for 
pool 1, it is accounted only for 14.1% of the variation. The 
majority of the variation was due to random error (47.2%) 
and day (22.9%). For pool 2, the variation due to the center 
effect was much larger (69.3%) compared to day (9.6%) and 
random error (9.1%).
Imprecision of the Methods
The imprecision of the methods according to the CLSI 
EP15-A3 guideline is presented in Table 1. Overall, coeffi-
cients of variation (CV) for the automated methods were bet-
ter than the desirable intra-individual CV (7.6%) [8], except 
for GR on pool 1 on both Elecsys and iSYS assays. For the 
IDS ELISA, the CV was > 7.6% on both pools in DK and 
on pool 1 in BE. In GR, the CV was < 7.6% for both pools.
Analysis of Patient Samples
Comparison Plasma vs. Serum
All Passing-Bablok regressions for comparisons between 
serum and plasma for each assay are presented in Table 2. 
The slope observed between plasma and serum for IDS-
iSYS method was higher (1.15) compared with the other 
two methods (both at 1.02).
For the Elecsys assay, the V-Shape model (Fig. 2a) shows 
that, overall, 97.6% of the observations fitted within the lim-
its with very little center disparities (98.0% in BE, 92.8% in 
UK, 99.5% in GR and 100% in DK). With iSYS, the over-
all agreement was 84.4% (Fig. 2b), mainly due to the poor 
agreement observed in BE (57.2%), whereas the other three 
centers presented a much better concordance, > 90%. Of 
note, BE is the center where the samples have been stored for 
the longest period (up to 2 years) compared to the other three 
centers (< 6 months). For IDS ELISA (Fig. 2c), the results 
of the V-shape showed an overall agreement of 88.9% with 
some disparities between the centers (90.5% in BE, 79.6% 
in GR, and 97.7% in DK).
Table 1  Imprecision (CV%) 
Roche Elecsys, IDS-iSYS, and 
IDS ELISA of ß-CTX assays 
according to the CLSI EP15-A3 
guideline
The values in bold are those higher than the desirable coefficient of variation (7.6%), based on intra-indi-
vidual variation of the biomarker
NP not performed
Elecsys IDS-iSYS ELISA
Pool 1 Pool 2 Pool 1 Pool 2 Pool 1 Pool 2
ALL 11.3 13.3 15.6 9.1 19.3 22.0
BE 3.3 2.1 6.7 4.5 8.8 5.0
DK 2.9 3.5 6.1 2.0 8.6 10.4
GR 8.2 2.4 12.2 4.7 6.9 2.0
UK 7.0 4.6 7.2 2.5 NP NP
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Comparison of Methods in Plasma and Serum
Elecsys vs. IDS‑iSYS
In plasma, the Passing-Bablok regression on the rela-
tionship between the Elecsys and iSYS assays was Roche 
Elecsys = 0.85*IDS-iSYS + 72.3 and in serum, it was 
Roche Elecsys = 0.97*IDS-iSYS + 96.1 (Table 3).
The V-shaped model shows that, overall, 74.5% of the 
values were within the limits for plasma vs. 41.7% only 
for serum. Disparities between centers were important: 
for plasma, the percentage of samples comprised within 
the limits was 80.2%, 63.6%, 73.1%, and 81.5% for BE, 
UK, GR, and DK, respectively. It was even more marked 
in serum with 20.7%, 29.4%, 86.8%, and 19.0% of the 
samples from BE, UK, GR, and DK present in the defined 
limits, respectively (Fig. 3a, b).
In the center GR, the Bland Altman plots showed that 
the difference between the iSYS and Elecsys assays sys-
tematically increased with increasing ß-CTX concentra-
tions in both plasma and serum (iSYS providing higher 
concentrations than Elecsys). This picture is very differ-
ent from the three other centers, where iSYS generally 
gave lower values than the Elecsys assay. That was par-
ticularly true for serum.
IDS‑iSYS vs. IDS ELISA
In plasma, the Passing-Bablok regression on the relation-
ship between iSYS and ELISA was IDS-iSYS = 0.95*IDS 
ELISA-25, and in serum, it was iSYS = 0.84*IDS ELISA-37 
(Table 3). The Bland–Altman plots (Fig. 3c, d) showed that 
iSYS generally gave lower ß-CTX values than the ELISA. 
That was specifically also true for serum where we observed 
a similar picture to what has been observed in serum when 
we compared the iSYS and Elecsys assays (see above) 
(Fig. 3c, d). The V-shape limits showed an overall agree-
ment of 77.0% for plasma vs. 47.3% for serum with large 
disparities between centers: 84.5%, 59.1%, and 89.8% of the 
values were comprised in the limits in plasma for BE, GR, 
and DK, respectively, whereas they were of 37.8%, 38.6%, 
and 71.9% in serum for BE, GR, and DK, respectively.
Elecsys vs. IDS ELISA
In plasma, the Passing-Bablok regressions on the relation-
ship between the Elecsys and ELISA assays was Roche 
Elecsys = 0.81*IDS ELISA + 43, and in serum, the rela-
tion was Elecsys = 0.80*IDS ELISA + 48 (Table 3). The 
Bland Altman plots (Fig. 3e, f) show a marked decrease 
in differences with increasing values in both media in GR, 
Table 2  Passing-Bablok 
correlation between ß-CTX run 
in plasma (y) and serum (x)
NP not performed
Roche Elecsys IDS-iSYS IDS ELISA
ALL
 Slope (95% CI) 1.02 (1.01; 1.04) 1.15 (1.14; 1.17) 1.03 (1.01; 1.05)
 Intercept (95% CI) − 10.9 (− 14.1; − 7.5) 6.8 (4.2; 9.5) − 10.1 (− 16.7; − 4.7)
 n 778 794 567
BE
 Slope (95% CI) 1.04 (1.02; 1.07) 1.30 (1.27; 1.32) 1.04 (1.00; 1.08)
 Intercept (95% CI) − 12.5 (− 20.4; − 6.0) 4.8 (− 1.6; 10.7) 0.7 (− 18.0; 13.8)
 n 200 200 190
DK
 Slope (95% CI) 0.95 (0.94; 0.97) 1.09 (1.06; 1.12) 0.98 (0.95; 1.00)
 Intercept (95% CI) − 7.1 (− 10.6; − 4.9) 16.1 (11.4; 22.1) − 7.2 (− 10.0; − 1.7)
 n 184 192 176
GR
 Slope (95% CI) 1.04 (1.02; 1.06) 1.17 (1.15; 1.19) 1.00 (0.95; 1.05)
 Intercept (95% CI) − 0.2 (− 8.0; 7.5) − 12.7 (− 20.3; − 5.0) 10.4 (− 11.5; 32.8)
 n 199 204 201
UK
 Slope (95% CI) 0.95 (0.93; 0.98) 1.13 (1.11; 1.15) NP
 Intercept (95% CI) 2.3 (− 2.7; 8.7) 2.9 (− 1.1; 6.0)
 n 195 200
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similarly to that observed when comparing Elecsys and 
iSYS. Centers BE and DK were very close in serum and 
plasma, presenting a slight increase in both media. This 
was confirmed by the V-shape limits showing percentages 
of samples between the limits of 86.9 and 85.2% in BE for 
plasma vs. serum compared to 87.3% and 85.2% in DK. 
The center GR had only 29.1% and 28.1% of the samples 
within the V-shape, which impacted the overall percent-
age of agreement (66.3 and 65.2% for plasma and serum, 
respectively).
To identify factors contributing to the variation between 
the ß-CTX values generated by the three assays, we cal-
culated multivariable models with age, sex, center, BMI, 
weight, height, BMD, fasting status, and medication as inde-
pendent covariates (data not shown). The two variables that 
appeared in all models were age and center, with center hav-
ing the largest effect and age a significant but small effect.
Finally, the CCC showed that the degree of agree-
ment between the methods was also center dependent and 
ranged from “poor” to “substantial.” Overall, the degree of 
Fig. 2  Bland–Altman plots and V-shape models comparing values observed in plasma vs. serum on Elecsys (a), iSYS (b), and ELISA (c)
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agreement was better in plasma than in serum (Table 4). 
Indeed, in plasma, the degree of agreement was moderate for 
Elecsys vs. iSYS and for iSYS vs. ELISA and was poor for 
Elecsys vs. ELISA, whereas in serum, it was poor whatever 
the compared methods.
Table 3  Passing-Bablok regression analyses of ß-CTX values performed with Roche Elecsys, IDS-iSYS, and IDS ELISA assays on serum and 
plasma specimens
PLASMA

















































































X IDS-iSYS IDS ELISA











































The upper line of result corresponds to the slope (95% confidence interval) and the second line to the intercept (95% confidence interval)
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Analysis of Internal Quality Control Results
Each center was free to run the QC according to their rou-
tine procedure. There were 3 levels of QC for iSYS which 
were run 19 times in BE, 10 times in DK, 12 times in GR, 
and 5 times in UK. The 95% confidence intervals method 
(Tukey) shows that no significant difference was observed 
between BE, DK, and GR in any of the 3 controls, whereas 
UK presented lower values ranging from − 14 to − 8%. For 
the Elecsys assay, there were 2 levels of QC that were run 
19 times in BE, 10 times in DK, 20 times in GR, and 5 times 
in UK. The 95% confidence intervals method shows that, 
for level 1, there was a non-significant trend for GR to have 
lower QC results, whereas for level 2, there was a significant 
difference of approximately 7% between BE and GR and 
between DK and GR.
Fig. 3  Bland–Altman and V-shape models comparing values observed in serum vs. plasma on iSYS vs. Elecsys (a, b), iSYS vs. IDS ELISA (c, 
d) and Elecsys vs. IDS ELISA (e, f). The bold dotted lines correspond to the bias ± 1.96 SD of the differences
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Discussion
Bone turnover markers, and notably bone resorption mark-
ers, are commonly used to monitor patients’ response to 
pharmacological treatment and adherence [2]. They have 
the great advantage, over bone mineral densitometry, in that 
they change rapidly following initiation of treatment, and 
these changes have suggested an association with reduction 
in fracture risk [11]. There would, thus, be a great benefit 
to follow patients with these markers, but many clinicians 
raise concerns before using them in clinical practice for the 
following reasons. First, these markers are very sensitive to 
pre-analytical variation including circadian rhythm and food 
intake [12]. Standardized procedures for specimen collection 
are, thus, mandatory for optimal patient follow-up. Second, 
reference ranges are not always correctly established and 
information on intra-individual variation is scarce. Third, 
there is variation between values generated by the different 
routine clinical assays due to non-availability of higher order 
reference methods (e.g., LCMS/MS methods) or internation-
ally accepted reference standard material for the calibration 
of these assays. ß-CTX is a complex analyte in biological 
fluids, existing in type I collagen breakdown products rang-
ing in molecular weight between 1000 and 10,000 Da [13]. 
For these reasons, IOF and IFCC have established a Com-
mittee for the standardization of bone marker assays, whose 
task was to standardize or harmonize (as technically feasible 
or appropriate at this time) clinical ß-CTX assays available 
for routine and research use, in serum and EDTA plasma.
Indeed, available data on method comparison for ß-CTX 
are scarce. An indirect comparison performed by one of us 
(RE) showed that upper reference limits were different when 
ß-CTX was measured in serum with the Roche Elecsys assay 
and the Nordic Biosciences ELISA (that later became IDS 
ELISA), ELISA providing a higher upper reference limit 
than Elecsys [14]. Similar data were shown in a recent 
comparison between the IDS-iSYS and the Roche Elecsys 
assays [15]. In a short communication, another one of us 
(EC) showed that the Passing-Bablok regression for serum 
ß-CTX with Roche Elecsys vs. IDS-iSYS assays was Roche 
Elecsys = 0.89*IDS-iSYS + 21.6 [16]. Chubb et al. evaluated 
ß-CTX values measured in EDTA plasma with the Roche 
Elecsys, IDS-iSYS, and IDS ELISA assays in 161 fasting 
men and women presenting to a bone clinic [6]. Comparing 
IDS-iSYS and Roche Elecsys, they found a huge propor-
tional bias (0.62) and a systematic bias comparable to that 
reported here, while comparison with the IDS ELISA data 
yielded results that were more discrepant than the current 
data [6]. Wheater et al. also compared ß-CTX in sera of 72 
self-reported healthy volunteers and 55 rheumatoid arthritis 
patients on Roche Elecsys and IDS-iSYS assays and found 
a large proportional bias of 1.29 (95% CI: 1.24; 1.34) and 
a constant bias of − 24 µg/L (95%CI: − 34; − 13) [17]. 
Finally, another of us (NRJ) recently compared 2308 serum 
ß-CTX levels measured with the IDS-iSYS and Roche Elec-
sys assays on samples stored at − 80 °C for < 2 years. The 
regression equation was CTX IDS-iSYS = 1.39*CTX Roche 
Elecsys − 139.75 [18].
In this study, we have reported the Passing-Bablok regres-
sions equations for ß-CTX values in serum and plasma spec-
imens for each of the routine clinical ß-CTX assays cur-
rently available and for comparisons of each of the assays in 
both serum and plasma. We have also compared the meth-
ods using Bland–Altman plots and V-shapes limits for the 
regression of differences on averages.
Our results show substantial variation between methods. 
Specifically, the largest variations were observed for
Fig. 3  (continued)
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1. Serum vs. plasma for iSYS in BE and
2. Elecsys vs. iSYS and ELISA in GR.
To further explore these variations, 80 patients samples 
(serum and EDTA plasma), stored in GR at − 80 °C were 
Table 4  Concordance 
correlation coefficients (CCC), 
Pearson correlation coefficient 
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reanalyzed in GR in 2019 on the cobas® platform by the 
Elecsys assay and shipped to BE where they were reanalyzed 
on cobas, together with 80 samples stored in BE. Compared 
to the results obtained in 2017, the Passing-Bablok regres-
sion of the Elecsys plasma values of the 80 BE patients was 
CTX (2017) = 1.11 × CTX (2019)—7 whereas the Pass-
ing-Bablok of the 80 GR patients rerun in GR was CTX 
(2017) = 0.90 × CTX (2019)—9. The Passing-Bablok of the 
GR samples run in GR and rerun in BE (both in 2019) was 
GR = 1.00 × BE—1.2. Long-term stability studies on ß-CTX 
are scarce. One study has shown that no decrease could be 
observed in concentrations after 3 years storage at − 80 °C 
[19]. However, if we assume that long-term storage of sam-
ples and two cycles of freeze thawing can only lead to some 
slight decrease in the concentration of the analyte, this new 
set of results shows that the results obtained on the cobas 
instrument in GR in 2017 were probably falsely low, even 
if the curves of the cobas and the quality controls of the 
company were within the specified limits.
Compared to 2017, the 2019 ß-CTX values observed on 
the BE samples decreased by 13.5% and 8.7% on the cobas 
analyzer in serum and plasma, respectively. On iSYS, the 
percentage of decrease of ß-CTX in plasma samples was 
rather similar (− 7.5% and − 8.4% for the BE and GR 
samples, respectively). However, the decrease of values 
obtained on serum with iSYS was much larger: 27.6% and 
22.6% for BE and GR samples, respectively. The reason 
why ß-CTX decreased more in serum on iSYS are unclear 
but may be linked to the configuration of the assay. Indeed, 
the iSYS assay uses a pair of monoclonal antibodies tar-
geted against the octapeptide, whereas Elecsys and IDS 
ELISA kits use a pair of polyclonal/monoclonal antibod-
ies. The difference in pH of stored serum and plasma 
samples (mean pH of a subset of 10 of these samples 
was 7.29 for serum and 8.06 for EDTA plasma) and/or 
inactivation of proteases by chelation of divalent cations 
by EDTA and/or pH could lead to a change in the con-
formation of the peptide. This change could be detected 
by the monoclonal/monoclonal sandwich but not by the 
polyclonal/monoclonal one. Since BE samples have been 
stored for a much longer period compared to GR, UK, and 
DK counterparts, the larger difference between plasma and 
serum observed on iSYS in the BE center could, thus, be 
due to this stability issue. Herrmann et al. have shown 
that at a pH > 8.0, serum ß-CTX concentration (measured 
by the Elecsys assay) remained relatively stable for sev-
eral(?) days if samples were stored at + 4 °C [20]. Later on, 
Qvist et al. evaluated long-term ß-CTX stability at lower 
temperatures [19]. They used the Elecsys and the former 
Nordic Biosciences ELISA assay that uses a pair of mono-
clonal antibodies similarly to the IDS-iSYS. As already 
mentioned, these authors did not find any degradation of 
ß-CTX after 3 years of storage at − 80 °C, contrary to us, 
with any of the 2 kits. It must be noted, however, which 
the pH they observed in serum was much more basic than 
what we found. These discrepancies deserve some more 
investigations.
Imprecision also varied among the sites, particularly with 
regard to the ELISA method suggesting a higher degree of 
operator dependency for the manual assay.
The CCC is also an interesting way to compare methods. 
In this study, the CCC is better in plasma vs. serum and 
varied according to the center for the same method. Even if 
far from perfect, these results are, however, in line with what 
can be expected from another biomarkers, like 25(OH)D for 
instance [21, 22].
The strengths of this study are the multicenter approach, 
the large number of participants, the use of serum and 
plasma, and the robustness of the pre-analytical and ana-
lytical methods. Even though we attempted to harmonize 
the criteria for recruitment of patients, not all were fasting 
at the time of specimen collection, which might be perceived 
as a weakness of our study. It is known that fasting reduces 
the within-individual biological variability of ß-CTX [23]. 
However, this study was purely an analytical comparison of 
methods, and no follow-up of the patients was performed. 
We have identified that the relationship between the Elecsys 
and iSYS ß-CTX values is not significantly different between 
GR and BE (all fasting) and DK and UK (not all fasting), 
which suggests that food intake does not appear to have any 
impact on the relationship between the ß-CTX values pro-
duced by the various assays.
In conclusion, we report the results of a multicenter 
evaluation of ß-CTX with the current assays used in clini-
cal laboratories and have derived regression equations for 
the interconversion of ß-CTX results assayed on serum and 
plasma specimens and between Roche cobas e and IDS-
iSYS immunoassay platforms or ELISA plates. We identified 
1. significant variation between the individual centers, each 
of whom is experienced with running these assays in clinical 
practice. Unfortunately, no useful regression equation could 
be calculated to harmonize results obtained with the differ-
ent platforms, mainly because of the large between-center 
variations. 2. Our results reinforce our previous recommen-
dation on the use of EDTA plasma over serum (especially 
in large epidemiological studies and therapeutic trials where 
the recruitment may be very long), and we recommend that 
patients are followed by the same method. For that purpose, 
we also recommend that laboratories identify the assay used 
for ß-CTX determination on their protocols.
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